INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

Mr. Egge has over 25 years of experience in the biopharmaceutical industry, building commercial organizations and successfully bringing innovative therapeutic products to market.

INOVIO is poised to become a commercial-stage company, with plans to submit a biologics license application for INO-3107 in the second half of 2024 under the U.S. Food and Drug Administration’s accelerated approval path.

MEETING IN PLYMOUTH, Pa., July 2, 2024 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV, cancer and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will lead the commercial strategy and operations of the company as it prepares for the potential commercial launch of its first DNA medicinal product, INO-3107, as a treatment for recurrent respiratory papillomatosis (RRP).

“We are pleased to welcome Steve to INOVIO and look forward to adding his expertise to our team as we continue to prepare for the 2025 commercial launch of INO-3107, if approved by the FDA for RRP,” said Dr. Jacqueline SheaPresident and CEO of INOVIO. “Steve joins us at an exciting time as we prepare to become a commercial-stage company while developing multiple product candidates that address unmet medical needs. His experience in launching new products, gaining market share in competitive environments and advancing broad therapeutic areas will be beneficial to the development and implementation of our commercial plans, as will his expertise in immunology and vaccines, HPV and rare diseases.”

“This is a great time to join INOVIO as the company has the opportunity to bring to market the first treatment option for patients with RRP, a rare and devastating HPV-related disease that significantly impacts quality of life,” said Mr. Egge. “I look forward to working with the talented INOVIO team and continuing our ongoing efforts to expand the company’s strategy and commercial capabilities.”

Mr. Egge joins INOVIO from Sumitomo Pharma (formerly Myovant Sciences, acquired by Sumitovant Biopharma, a subsidiary of Sumitomo Pharma, in 2023), where as Senior Vice President and General Manager, Women’s Health, he was responsible for building the commercial leadership team, accelerating the launch of Myfembree® and helping to lead the company’s expansion into new indications. Mr. Egge was with Merck for twenty years, where he held a number of leadership positions within the commercial division, including leading Merck’s HPV vaccine franchise, and serving as Chief Marketing Officer for the Vaccines Division, where he oversaw the launch of new indications for GARDASIL®, the relaunch of ZOSTAVAX®, and the launch planning for GARDASIL9® and VAXELIS®. Mr. Egge also served as Global Chief Commercial Officer for the Merck Fertility Franchise, where he oversaw the launch of ELONVA® in markets outside the United States. Following his tenure at Merck, Mr. Egge served as Senior Vice President at Genfit Corp., a French biotechnology company focused on liver diseases, where he was responsible for commercial planning and business development.

About INOVIO’s DNA Medicines Platform
INOVIO’s DNA drug delivery platform has two innovative components: precision-engineered DNA plasmids, delivered by INOVIO’s patented medical device, CELLECTRA®. INOVIO uses patented technology to design its DNA plasmids, which are small, circular DNA molecules that act like software that the body’s cells can take up to produce specific proteins to fight disease. INOVIO’s patented DNA drug delivery devices, CELLECTRA®, are designed to optimally deliver DNA drugs to the body’s cells without the need for chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response that has historically occurred with viral vector platforms.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines that help treat and protect people from HPV-related diseases, cancers and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to make its own tools to fight disease. For more information, visit www.inovio.com.

Cell® is a trademark of INOVIO.
GARDASIL®GARDASIL9®ZOSTAVAX® and ELONVA® are trademarks of Merck and Co., Inc.
VACCINE® is a trademark of The MSP Vaccine Company.
My woman® is a trademark of Sumitomo Pharma Switzerland GmbH.

Forward-looking statements
This press release contains certain forward-looking statements about our business, including our plans to develop and commercialize DNA medicines and our expectations regarding our research and development programs, including our planned submission of a BLA in the second half of 2024 and our planned commercial launch of INO-3107 if we receive regulatory approval. Actual events or results may differ from the expectations expressed herein due to a number of factors, including the uncertainties inherent in preclinical studies, clinical trials, product development programs, and commercialization activities and results, the availability of funds to support continuing research and studies to prove the safety and efficacy of electroporation technology as a delivery mechanism or to develop viable DNA medicines, our ability to support our DNA medicine pipeline, the ability of our collaborators to achieve development and commercialization milestones for products we license and to sell products that will allow us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions we are targeting or are collaborators with, including alternatives that may be more effective or cost-effective than any therapy or treatment we and our collaborators hope to develop, product liability issues, issues related to patents and whether they or licenses thereto will provide us with meaningful protection against others using the technologies covered by them, whether such rights the property is enforceable or defensible or infringes or allegedly infringe the rights of others or may withstand invalidity claims and whether we can fund or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate spending, evaluations of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government health care proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023our quarterly report on Form 10-Q for the quarter ended March 31, 2024and other documents filed by us from time to time with the Securities and Exchange Commission. There can be no assurance that any of our product candidates will be successfully developed, manufactured or commercialized, that the results of clinical trials will support the regulatory approvals required to bring our products to market, or that any forward-looking information contained herein will prove to be accurate. Forward-looking statements speak only as of the date of this announcement, and we undertake no obligation to update or revise these statements, except as required by law.

Communication
Media: Jennie Wilson (267) 429-8567 (email protected)
Investors: Thomas Hong (267) 440-4298 (email protected)

SOURCE INOVIO Pharmaceuticals, Inc.